{
    "abstract": "Menopause-associated insomnia is commonly associated with other symptoms (hot flashes, depression, anxiety). Given frequent symptom cooccurrence, therapies targeting sleep may provide an important approach to treatment during midlife.\nPeri/postmenopausal women (40-65 years old) with sleep-onset and/or sleep-maintenance insomnia cooccurring with hot flashes and depressive and/or anxiety symptoms were randomized to eszopiclone 3 mg orally or placebo in a double-blinded, crossover 11 week trial. Changes in the Insomnia Severity Index (ISI) scale and secondary outcomes (diary-based sleep parameters, depression/anxiety, hot flashes, quality of life) were analyzed using repeated-measure linear models.\nOf 59 women, 46 (78%) completed the study. Eszopiclone reduced ISI scores by 8.7 + or - 1.4 more points than placebo (P < .0001). Eszopiclone improved (P < .05) all sleep parameters, depressive symptoms, anxiety symptoms, quality of life, and nighttime but not daytime hot flashes.\nEszopiclone treats insomnia and cooccurring menopause-related symptoms. Our results provide evidence that hypnotic therapies may improve multiple domains of well-being during midlife.",
    "authors": [
        {
            "affiliation": "Perinatal and Reproductive Psychiatry Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. hjoffe@partners.org",
            "firstname": "Hadine",
            "initials": "H",
            "lastname": "Joffe"
        },
        {
            "affiliation": null,
            "firstname": "Laura",
            "initials": "L",
            "lastname": "Petrillo"
        },
        {
            "affiliation": null,
            "firstname": "Adele",
            "initials": "A",
            "lastname": "Viguera"
        },
        {
            "affiliation": null,
            "firstname": "Alexia",
            "initials": "A",
            "lastname": "Koukopoulos"
        },
        {
            "affiliation": null,
            "firstname": "Kate",
            "initials": "K",
            "lastname": "Silver-Heilman"
        },
        {
            "affiliation": null,
            "firstname": "Adriann",
            "initials": "A",
            "lastname": "Farrell"
        },
        {
            "affiliation": null,
            "firstname": "Gary",
            "initials": "G",
            "lastname": "Yu"
        },
        {
            "affiliation": null,
            "firstname": "Michael",
            "initials": "M",
            "lastname": "Silver"
        },
        {
            "affiliation": null,
            "firstname": "Lee S",
            "initials": "LS",
            "lastname": "Cohen"
        }
    ],
    "conclusions": "Eszopiclone treats insomnia and cooccurring menopause-related symptoms. Our results provide evidence that hypnotic therapies may improve multiple domains of well-being during midlife.",
    "copyrights": "Copyright 2010 Mosby, Inc. All rights reserved.",
    "doi": "10.1016/j.ajog.2009.10.868",
    "journal": "American journal of obstetrics and gynecology",
    "keywords": [],
    "methods": null,
    "publication_date": "2009-12-29",
    "pubmed_id": "20035910",
    "results": "Of 59 women, 46 (78%) completed the study. Eszopiclone reduced ISI scores by 8.7 + or - 1.4 more points than placebo (P < .0001). Eszopiclone improved (P < .05) all sleep parameters, depressive symptoms, anxiety symptoms, quality of life, and nighttime but not daytime hot flashes.",
    "title": "Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial.",
    "xml": "<Element 'PubmedArticle' at 0x788501dbb6a0>"
}